4//SEC Filing
Kiener Peter A 4
Accession 0001209191-23-021201
CIK 0001645460other
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 4:05 PM ET
Size
9.1 KB
Accession
0001209191-23-021201
Insider Transaction Report
Form 4
Kiener Peter A
Director
Transactions
- Exercise/Conversion
Common Stock
2023-03-23$2.86/sh+9,682$27,691→ 9,682 total - Exercise/Conversion
Stock Option (right to buy)
2023-03-23−9,682→ 96,062 totalExercise: $2.86Exp: 2023-03-23→ Common Stock (9,682 underlying) - Sale
Common Stock
2023-03-23$3.28/sh−9,325$30,586→ 357 total
Footnotes (3)
- [F1]Sale to cover exercise price of cashless exercise of stock option.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023.
Documents
Issuer
Cue Biopharma, Inc.
CIK 0001645460
Entity typeother
Related Parties
1- filerCIK 0001328146
Filing Metadata
- Form type
- 4
- Filed
- Mar 26, 8:00 PM ET
- Accepted
- Mar 27, 4:05 PM ET
- Size
- 9.1 KB